Pfizer Long Term Debt 2010-2024 | PFE

Pfizer long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Pfizer long term debt for the quarter ending March 31, 2024 was $61.307B, a 93.37% increase year-over-year.
  • Pfizer long term debt for 2023 was $61.538B, a 87.14% increase from 2022.
  • Pfizer long term debt for 2022 was $32.884B, a 9.15% decline from 2021.
  • Pfizer long term debt for 2021 was $36.195B, a 2.53% decline from 2020.
Pfizer Annual Long Term Debt
(Millions of US $)
2023 $61,538
2022 $32,884
2021 $36,195
2020 $37,133
2019 $35,955
2018 $32,909
2017 $33,538
2016 $31,398
2015 $28,740
2014 $31,541
2013 $30,462
2012 $31,036
2011 $34,926
2010 $38,410
2009 $43,193
Pfizer Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $61,307
2023-12-31 $61,538
2023-09-30 $61,048
2023-06-30 $61,356
2023-03-31 $31,704
2022-12-31 $32,884
2022-09-30 $32,629
2022-06-30 $34,294
2022-03-31 $35,656
2021-12-31 $36,195
2021-09-30 $36,250
2021-06-30 $35,354
2021-03-31 $35,347
2020-12-31 $37,133
2020-09-30 $49,785
2020-06-30 $50,529
2020-03-31 $36,281
2019-12-31 $35,955
2019-09-30 $36,044
2019-06-30 $36,168
2019-03-31 $35,733
2018-12-31 $32,909
2018-09-30 $33,652
2018-06-30 $28,935
2018-03-31 $31,831
2017-12-31 $33,538
2017-09-30 $34,503
2017-06-30 $34,191
2017-03-31 $36,330
2016-12-31 $31,398
2016-09-30 $30,437
2016-06-30 $30,457
2016-03-31 $27,824
2015-12-31 $28,740
2015-09-30 $29,079
2015-06-30 $26,729
2015-03-31 $29,370
2014-12-31 $31,541
2014-09-30 $31,666
2014-06-30 $32,267
2014-03-31 $27,649
2013-12-31 $30,462
2013-09-30 $31,812
2013-06-30 $31,532
2013-03-31 $31,481
2012-12-31 $31,036
2012-09-30 $31,083
2012-06-30 $30,868
2012-03-31 $33,543
2011-12-31 $34,926
2011-09-30 $35,399
2011-06-30 $35,723
2011-03-31 $35,308
2010-12-31 $38,410
2010-09-30 $39,010
2010-06-30 $37,765
2010-03-31 $38,281
2009-12-31 $43,193
2009-09-30 $32,402
2009-06-30 $31,864
2009-03-31 $21,064
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $162.291B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01